Mihwa Hwang

Targeted Therapy Branch, Goyang 10408
Goyang, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: January 22, 2025

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Journal: MedComm

Published: December 30, 2024

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones.

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones.

Journal: Experimental & molecular medicine

Published: November 13, 2024

Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy.

Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy.

Journal: Cancers

Published: December 27, 2023

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.

Journal: Cancers

Published: June 06, 2023

Ataxia-Telangiectasia Mutated Is Involved in Autolysosome Formation.

Ataxia-Telangiectasia Mutated Is Involved in Autolysosome Formation.

Journal: Biomolecules & therapeutics

Published: January 07, 2023

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 21, 2022

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.

Journal: Translational lung cancer research

Published: March 07, 2022

EI24, as a Component of Autophagy, Is Involved in Pancreatic Cell Proliferation.

EI24, as a Component of Autophagy, Is Involved in Pancreatic Cell Proliferation.

Journal: Frontiers in oncology

Published: February 27, 2019

DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.

DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.

Journal: Oncotarget

Published: June 18, 2015

Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.

Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.

Journal: PloS one

Published: May 03, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026